lymphocyt
transform
product
neutralis
antibodi
develop
antirabi
igg
antibodi
studi
ten
healthi
volunt
respons
middot
ml
human
diploidcel
strain
hdc
rabi
vaccin
administ
one
occas
divid
dose
intraderm
id
site
ten
volunt
rapidli
develop
substanti
titr
rabi
antibodi
eight
ten
lymphocyt
immunolog
stimul
hdc
rabiesviru
antigen
postexposur
treatment
middot
ml
hdc
vaccin
given
id
site
complet
protect
fourteen
rabbit
death
street
viru
result
suggest
develop
countri
patient
could
protect
small
volum
potent
tissuecultur
vaccin
administ
intraderm
shortli
exposur
introduct
fortyf
peopl
sever
bitten
rabid
dog
wolv
iran
treat
exposur
new
rabi
vaccin
produc
cultur
human
diploid
cell
except
one
also
receiv
one
inject
rabi
immun
serum
treatment
contrast
past
experi
vaccin
result
protect
individu
rabi
resound
success
repeat
trial
germani
usa
use
dose
human
diploidcel
strain
hdc
rabi
vaccin
human
rabi
immun
globulin
thu
almost
centuri
post
exposur
treatment
man
began
effect
antirabi
prophylaxi
appear
achiev
except
rabi
problem
impoverish
area
world
annual
percaput
expenditur
health
care
often
far
less
cost
singl
ml
dose
hdc
vaccin
consequ
potent
tissuecultur
vaccin
seldom
use
third
world
need
effect
less
expens
method
treatment
prompt
us
investig
possibl
administ
potent
vaccin
econom
effici
present
previou
studi
shown
substanti
titr
antibodi
achiev
small
quantiti
hdc
vaccin
administ
intraderm
id
rout
cost
vaccin
reduc
paper
report
antibodi
cellmedi
immun
respons
man
multisit
id
vaccin
applic
method
postexposur
protect
rabbit
appear
possibl
id
rout
could
appli
success
post
exposur
treatment
man
approv
volunt
studi
given
northwick
park
hospit
ethic
committe
hdc
vaccin
ml
given
id
singl
occas
ten
volunt
site
medial
later
aspect
upper
arm
thigh
blood
sampl
test
lymphocyt
transform
antibodi
determin
taken
vaccin
day
later
blood
sampl
antibodi
titrat
taken
day
four
subject
vaccin
dermojet
injector
six
remain
volunt
given
vaccin
needl
tuberculin
syring
volunt
receiv
antirabi
vaccin
previous
nuchal
muscl
fortytwo
new
zealand
white
rabbit
inocul
rabbit
ofa
first
mousebrainpassag
arcticfox
rabi
viru
isol
two
separ
site
ml
side
h
later
fourteen
rabbit
given
ml
hdc
vaccin
intramuscularli
im
left
forelimb
fourteen
other
receiv
id
inject
ml
vaccin
limb
remain
fourteen
use
control
receiv
prophylaxi
anim
observ
month
sign
rabi
none
rabbit
expos
rabi
previous
immunis
diseas
studi
wholevirion
hdc
rabi
vaccin
iinstitut
merieux
lot
r
antigen
valu
inactiv
use
blood
sampl
titrat
rabi
neutralis
antibodi
mous
neutralis
test
titr
iuml
calcul
refer
intern
standard
antiserum
rabi
viru
staten
seruminstitut
copenhagen
denmark
addit
sera
assay
igg
rabi
antibodi
enzym
immunoassay
elisa
use
modif
method
use
detect
coronaviru
antibodiesl
deg
k
g
nicholson
h
prestag
unpublish
absorb
valu
read
nm
flow
laboratori
titertek
multiskan
spectrophotomet
min
addit
substrat
rabi
antibodi
consid
present
opticaldens
read
test
sampl
greater
mean
standard
deviat
compar
dilut
neg
control
sera
enrich
tlymphocyt
popul
obtain
pass
thricewash
mononuclearcel
suspens
taken
top
ficolltriosil
gradient
pharmacia
fine
chemic
uppsala
sweden
twice
nylonfibr
column
cell
suspens
obtain
contain
less
b
lymphocyt
judg
stain
polyval
fluoresceinlabel
antihuman
immunoglobulin
reagent
enrich
blymphocyt
popul
obtain
sediment
rosett
form
lymphocyt
sheep
red
blood
cell
lymphocyt
human
cord
blood
nonvaccin
subject
use
control
hdc
rabiesviru
vaccin
linstitut
merieux
lot
r
exhaust
dialys
phosphatebuff
salin
pb
adjust
origin
volum
pb
use
antigen
phytohaemagglutinin
pha
purifi
grade
wellcom
laboratori
beckenham
use
control
concentr
mitogen
unitsml
cultur
contain
antigen
mitogen
cell
suspens
contain
x
lymphocyt
establish
microtitr
plate
puls
tritiat
thymidin
harvest
describ
previous
ph
indic
vaccin
needl
inocul
immedi
result
magentacolour
skin
bleb
inject
site
vaccin
dermojet
injector
gener
quicker
bleb
format
less
satisfactori
area
skin
especi
soft
appear
vaccin
enter
subcutan
tissu
method
inocul
also
associ
lower
titr
antibodi
occur
needl
inocul
fig
six
subject
inocul
needl
syring
day
neutralis
antibodi
rang
iuml
geometr
mean
titr
gmt
iuml
antirabi
igg
rang
gmt
peak
titr
viru
neutralis
antibodi
found
day
gmt
iuml
substanti
titr
still
present
day
vaccin
increment
cpm
lymphocyt
transform
express
ratio
cpm
valu
nonstimul
control
cultur
tabl
result
show
lymphocyt
eight
ten
vaccine
significantli
stimul
vitro
day
vaccin
blast
transform
occur
cell
three
four
peopl
given
vaccin
dermojet
injector
five
ofth
six
peopl
inocul
needl
syring
signific
differ
transform
increment
two
group
correl
found
transform
increment
titr
antirabi
igg
nine
fourteen
rabbit
develop
paralysi
die
infect
rabbit
ldso
streetrabi
viru
anim
forelimb
paralysi
develop
within
day
infect
progress
complet
paralysi
death
day
later
postexposur
treatment
singl
dose
hdc
vaccin
reduc
mortal
significantli
administr
ml
vaccin
im
gave
signific
fisher
exact
test
incomplet
protect
two
fourteen
anim
develop
paralysi
die
incub
period
day
none
fourteen
rabbit
die
receiv
id
inocul
ml
vaccin
limb
p
britain
franc
administr
hdc
vaccin
intraderm
rout
follow
substanti
titr
virusneutralis
antibodi
occasion
mild
local
system
reaction
also
shown
dose
ml
given
separ
site
singl
occas
rapidli
induc
high
titr
antibodi
present
report
confirm
observ
show
addit
earli
product
virusneutralis
antibodi
accompani
high
titr
antirabi
igg
earli
igg
respons
may
import
well
establish
neutralis
antibodi
igg
class
unlik
igm
neutralis
antibodi
confer
protect
anim
challeng
may
key
success
postexposur
treatment
man
possibl
role
cellmedi
immun
rabi
infect
poorli
understood
may
import
compon
host
immun
respons
report
transform
lymphocyt
occur
cell
taken
eight
ten
vaccine
first
x
ml
dose
establish
postexposur
regimen
hdc
vaccin
present
studi
separ
lymphocyt
subpopul
shown
blast
transform
tcell
respons
furthermor
occur
proport
vaccine
eight
often
found
previou
studi
quarter
volum
vaccin
clearli
high
titr
neutralis
antibodi
cellmedi
respons
import
protect
present
studi
suggest
obtain
equal
well
much
smaller
quantiti
vaccin
use
present
show
rabbit
could
complet
protect
inject
x
ml
dose
hdc
vaccin
intraderm
h
intranuch
infect
streetrabi
viru
contrast
nine
fourteen
control
die
rabi
incub
period
day
mean
day
oppon
administr
rabi
vaccin
id
rout
claim
technic
difficult
especi
elderli
young
nevertheless
mani
vaccin
routin
administ
id
rout
appar
success
consider
financi
save
seem
ampl
experiment
evid
justifi
postexposur
studi
hdc
vaccin
administ
id
rout
believ
would
ethic
potenti
great
import
develop
countri
k
g
n
partli
support
mrceli
lilli
travel
fellowship
us
nation
center
diseas
control
atlanta
ga
g
partli
support
mrc
grant
thank
dr
c
charbonni
llnstitut
merieux
gift
vaccin
request
reprint
address
k
g
n
